Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Evidence For Endothelial Involvement in Idiopathic Nephrotic Syndrome: A Role for CD93

Award Number: K08DK134761
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 07/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Evidence For Endothelial Involvement in Idiopathic Nephrotic Syndrome: A Role for CD93 - Project Summary/Abstract: Idiopathic Nephrotic Syndrome (INS) is the most common type of nephrotic syndrome in childhood, yet its cause remains unknown. Most authorities consider the disease to be mediated by an unknown circulating factor that directly binds the podocyte, causing podocyte activation and proteinuria. However, our group has shown that the disease may not be that simple and that there is also injury to the glomerular endothelial cells (GEnC) that line the inside of the capillary. We recently showed evidence of circulating endothelial biomarkers in ~90% of INS patients. In preliminary studies, we found that one specific endothelial protein, CD93, was especially important, which may relate to its ability to activate focal adhesion kinase (FAK), a protein that is activated in INS and causes podocyte injury. We found high CD93 expression in GEnC from kidney biopsies of INS patients and that levels of its soluble form were high in serum and urine in ~90% of ~300 patients. We also found that sera in relapse stimulate cultured GEnC to release CD93; and importantly, that activation of podocytes by relapsing sera could be blocked with an antibody to CD93. Our preliminary work also identifies urinary CD93 as predictor of kidney disease progression. Our data suggest that the pathogenesis of INS involves an intermediary step of GEnC activation that facilitates podocyte injury. Our central hypothesis is that circulating factors activate GEnC to release the soluble form of CD93, which, in turn, acts as (1) a predictive biomarker for kidney disease progression, and (2) mediator of podocyte activation via FAK signaling. In aim 1, we will study whether CD93, in glomeruli, urine or serum, predicts clinical outcomes and associates with structural and/or biological changes affecting glomeruli. This will be complemented by pilot studies to delineate the patterns of soluble CD93 across disease states, and its specificity across glomerular diseases. In aim 2, we will combine multiple in vitro approaches to identify the source of soluble CD93 and its effects on human podocytes. In aim 3, we will study the CD93 involvement in 2 classic animal models of INS (puromycin and adriamycin), and whether CD93 blockade prevents and/or mitigates proteinuria. Our hypothesis is innovative because GEnC are not considered to have an important role in INS. The combination of several approaches to assess endothelial injury and the inclusion of a large population provide rigor to the clinical studies. Integrating multiple cell systems and classic models of INS also provide a rigorous approach to test causality. Our proposal is highly translational and could lead to the identification of a novel prognostic and therapeutic target in INS. A four-year mentored career development plan has also been devised, which incorporates training in endothelial biology, precision medicine, and leadership by an experienced mentoring and advisory teams. The candidate’s long-term career goal is to become an independent investigator discovering biomarkers, mechanistic pathways, and targeted therapies in INS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $153,651 )
2026	2026	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	3/27/2026	NON-COMPETING CONTINUATION	$153,651
														Subtotal = $153,651

Issue Date FY: 2025 ( Subtotal = $153,651 )
2025	2025	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	3/28/2025	NON-COMPETING CONTINUATION	$153,651
														Subtotal = $153,651

Issue Date FY: 2024 ( Subtotal = $153,651 )
2024	2024	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	6/18/2024	NEW	$153,651
														Subtotal = $153,651

Grand Total All Awards = $460,953

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Evidence For Endothelial Involvement in Idiopathic Nephrotic Syndrome: A Role for CD93

Award Number: K08DK134761

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 07/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer